Aurinia Pharmaceuticals Inc. (AUPH) shareholders
Close on Nov 17, 2026Market cap $2.06BP/E 6.7Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Tang Capital Management, LLC Joint filing with Kevin Tang (10.00%), Tang Capital Partners, LP (5.60%) | 13,044,106 | 10.00% | 13D (active) amendment | Jun 2, 2026 |
| Kevin Tang Joint filing with Tang Capital Management, LLC (7.30%) | 10,029,500 | 7.30% | 13D (active) amendment | Feb 28, 2025 |
| BlackRock, Inc. | 8,921,049 | 6.20% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AUPH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 13,044,106 | 9.73% | $221.36M | +814,606 | 10.05% |
| BlackRock, Inc. | 8,193,085 | 6.11% | $139.04M | +347,564 | 0.00% |
| Goldman Sachs Group Inc | 5,619,401 | 4.19% | $95.36M | +4,185,893 | 0.01% |
| NEA Management Company, LLC | 3,969,834 | 2.96% | $67.37M | – | 4.24% |
| Two Sigma Investments, LP | 3,467,514 | 2.59% | $58.84M | +38,809 | 0.04% |
| Arrowstreet Capital, Limited Partnership | 3,264,062 | 2.44% | $55.39M | −20,306 | 0.02% |
| State Street Corp | 2,589,615 | 1.93% | $43.95M | +62,516 | 0.00% |
| Morgan Stanley | 2,308,244 | 1.72% | $39.17M | +75,696 | 0.00% |
| Marshall Wace, Llp | 2,044,007 | 1.53% | $34.69M | +169,410 | 0.03% |
| Geode Capital Management, LLC | 1,701,152 | 1.27% | $28.86M | +165,143 | 0.00% |
| Renaissance Technologies LLC | 1,548,035 | 1.16% | $26.27M | −115,800 | 0.04% |
| D. E. Shaw & Co., Inc. | 1,408,456 | 1.05% | $23.90M | −164,527 | 0.01% |
| Vanguard Portfolio Management LLC | 1,359,028 | 1.01% | $23.06M | +102,667 | 0.00% |
| Jacobs Levy Equity Management, Inc | 1,231,516 | 0.92% | $20.90M | +134,327 | 0.08% |
| Jupiter Asset Management Ltd | 1,094,475 | 0.82% | $18.57M | +291,056 | 0.09% |
| Lsv Asset Management | 1,079,447 | 0.81% | $18.32M | +39,871 | 0.03% |
| Nomura Holdings Inc | 978,602 | 0.73% | $16.61M | +9,692 | 0.02% |
| Aqr Capital Management LLC | 948,751 | 0.71% | $16.10M | −59 | 0.01% |
| Northern Trust Corp | 863,567 | 0.64% | $14.65M | +39,462 | 0.00% |
| Nuveen, LLC | 812,915 | 0.61% | $13.80M | +159,491 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 281 | 78M | 58.3% | 49 / 105 | 80 / 24 | 11M | 6M |
| Q1 2026 | 260 | 74M | 55.2% | 40 / 104 | 71 / 29 | 10M | 6M |
| Q4 2025 | 256 | 73M | 54.2% | 45 / 89 | 82 / 29 | 12M | 6M |
| Q3 2025 | 242 | 67M | 49.7% | 47 / 62 | 91 / 20 | 15M | 8M |
| Q2 2025 | 219 | 59M | 44.1% | 34 / 69 | 63 / 28 | 7M | 11M |
| Q1 2025 | 214 | 63M | 46.8% | 38 / 67 | 59 / 21 | 11M | 6M |
| Q4 2024 | 200 | 59M | 43.7% | 38 / 63 | 51 / 19 | 7M | 8M |
| Q3 2024 | 183 | 59M | 44.1% | 31 / 52 | 46 / 16 | 19M | 7M |
| Q2 2024 | 171 | 57M | 42.2% | 25 / 57 | 47 / 31 | 6M | 8M |
| Q1 2024 | 178 | 59M | 43.8% | 27 / 47 | 62 / 39 | 9M | 6M |
| Q4 2023 | 191 | 56M | 41.5% | 22 / 60 | 64 / 26 | 12M | 6M |
| Q3 2023 | 198 | 51M | 38.1% | 24 / 69 | 49 / 23 | 8M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
178 funds held AUPH in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AUPH | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Russell 2000 ETF | 3,062,402 | 2.29% | $51.97M | 0.06% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,303,109 | 0.97% | $19.39M | 0.06% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,101,324 | 0.82% | $18.69M | 0.12% | Jun 30, 2026 |
| iShares Biotechnology ETF | 800,933 | 0.60% | $13.59M | 0.15% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 613,258 | 0.46% | $9.40M | 0.05% | May 31, 2026 |
| Goldman Sachs U.S. Tax-Managed Equity Fund | 541,443 | 0.40% | $9.19M | 0.19% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 480,650 | 0.36% | $7.15M | 0.18% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 336,035 | 0.25% | $5.15M | 0.03% | May 31, 2026 |
| Goldman Sachs Small Cap Value Insights Fund | 334,685 | 0.25% | $4.98M | 0.38% | Jul 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 321,869 | 0.24% | $5.46M | 0.09% | Jun 30, 2026 |
| Goldman Sachs Small Cap Equity Insights Fund | 304,118 | 0.23% | $4.53M | 0.45% | Jul 31, 2026 |
| Schwab Small-Cap Index Fund | 288,413 | 0.22% | $4.29M | 0.06% | Jul 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 241,157 | 0.18% | $3.70M | 0.13% | May 31, 2026 |
| Federated Hermes MDT Small Cap Growth Fund | 237,798 | 0.18% | $3.54M | 0.42% | Jul 31, 2026 |
| Master Small Cap Index Series | 216,179 | 0.16% | $3.67M | 0.06% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kevin Tang | Chief Executive Officer, Director, 10% owner | 13,044,106 | 9.73% | Jun 2, 2026 |
| Peter Greenleaf | Chief Executive Officer, Director | 1,840,379 | 1.37% | Mar 3, 2026 |
| Stephen P. Robertson | Chief Legal Officer | 576,981 | 0.43% | Nov 16, 2026 |
| Ryan Cole | Chief Operating Officer | 116,144 | 0.09% | May 20, 2026 |
| Michael S. Hearne | Chief Financial Officer | 116,144 | 0.09% | May 20, 2026 |
| Greg Keenan | SVP, Chief Medical Officer | 154,449 | 0.12% | Mar 10, 2026 |
| Joseph M. Miller | Chief Financial Officer | 576,421 | 0.43% | Mar 3, 2026 |
| Matthew Maxwell Donley | Chief Operating Officer | 680,299 | 0.51% | Mar 3, 2026 |
| Kathleen Goetz | Director | – | – | Jun 8, 2026 |
| Craig A. Johnson | Director | 14,592 | 0.01% | Jun 8, 2026 |
| Jeffrey Allen Bailey | Director | 22,775 | 0.02% | Jun 8, 2026 |
| Tina Susan Nova | Director | – | – | Jun 8, 2026 |
| Karen L. Smith | Director | 24,807 | 0.02% | Nov 25, 2024 |
| David R.W. Jayne | Director | 56,499 | 0.04% | Nov 25, 2024 |
| Jill Leversage | Director | 26,453 | 0.02% | Nov 25, 2024 |
| Capital Management Llc Tang | 10% owner | – | – | Jun 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stephen P. Robertson Chief Legal Officer | Nov 13, 2026 | Sale | −11,867 | $15.97 | $189.52K | 576,981 |
| Stephen P. Robertson Chief Legal Officer | Sep 10, 2026 | Sale | −11,939 | $15.95 | $190.43K | 588,848 |
| Stephen P. Robertson Chief Legal Officer | Aug 21, 2026 | Sale | −20,975 | $16.97 | $355.95K | 600,787 |
| Kevin Tang Chief Executive Officer, Director, 10% owner | Jun 2, 2026 | Buy | +206,005 | $15.28 | $3.15M | 13,044,106 |
| Kevin Tang Chief Executive Officer, Director, 10% owner | Jun 1, 2026 | Buy | +99 | $15.34 | $1.52K | 12,838,101 |
| Kevin Tang Chief Executive Officer, Director, 10% owner | Jun 1, 2026 | Buy | +343,521 | $15.28 | $5.25M | 12,838,002 |
| Kevin Tang Chief Executive Officer, Director, 10% owner | May 29, 2026 | Buy | +262,682 | $15.31 | $4.02M | 12,494,481 |
| Kevin Tang Chief Executive Officer, Director, 10% owner | May 29, 2026 | Buy | +2,299 | $15.35 | $35.29K | 12,231,799 |
| Ryan Cole Chief Operating Officer | May 18, 2026 | Award | +116,144 | – | – | 116,144 |
| Stephen P. Robertson Chief Legal Officer | May 18, 2026 | Award | +115,541 | – | – | 621,402 |
| Michael S. Hearne Chief Financial Officer | May 18, 2026 | Award | +116,144 | – | – | 116,144 |
| Greg Keenan SVP, Chief Medical Officer | Mar 6, 2026 | Tax withholding | −8,069 | $14.32 | $115.55K | 154,449 |
| Kevin Tang Director | Mar 3, 2026 | Buy | +184,208 | $14.22 | $2.62M | 12,229,500 |
| Stephen P. Robertson EVP, General Counsel | Mar 2, 2026 | Tax withholding | −36,525 | $14.21 | $519.02K | 505,861 |
| Joseph M. Miller Chief Financial Officer | Mar 2, 2026 | Tax withholding | −37,511 | $14.21 | $533.03K | 576,421 |
| Peter Greenleaf Chief Executive Officer, Director | Mar 2, 2026 | Tax withholding | −100,890 | $14.21 | $1.43M | 1,840,379 |
| Kevin Tang Director | Mar 2, 2026 | Buy | +115,792 | $14.21 | $1.65M | 12,045,292 |
| Kevin Tang Director | Mar 2, 2026 | Buy | +83,561 | $14.33 | $1.20M | 11,929,500 |
| Matthew Maxwell Donley Chief Operating Officer | Mar 2, 2026 | Tax withholding | −40,761 | $14.21 | $579.21K | 680,299 |
| Stephen P. Robertson EVP, General Counsel | Feb 27, 2026 | Award | +59,090 | – | – | 542,386 |
| Joseph M. Miller Chief Financial Officer | Feb 27, 2026 | Award | +57,229 | – | – | 613,932 |
| Peter Greenleaf Chief Executive Officer, Director | Feb 27, 2026 | Award | +196,403 | – | – | 1,941,269 |
| Kevin Tang Director | Feb 27, 2026 | Buy | +300,000 | $13.90 | $4.17M | 11,629,500 |
| Kevin Tang Director | Feb 27, 2026 | Buy | +1,600 | $14.38 | $23.01K | 11,845,939 |
| Kevin Tang Director | Feb 27, 2026 | Buy | +214,839 | $14.12 | $3.03M | 11,844,339 |
| Greg Keenan SVP, Chief Medical Officer | Feb 27, 2026 | Award | +40,586 | – | – | 162,518 |
| Matthew Maxwell Donley Chief Operating Officer | Feb 27, 2026 | Award | +58,160 | – | – | 721,060 |
| Stephen P. Robertson EVP, General Counsel | Feb 20, 2026 | Tax withholding | −34,638 | $14.40 | $498.79K | 483,296 |
| Joseph M. Miller Chief Financial Officer | Feb 20, 2026 | Tax withholding | −32,424 | $14.40 | $466.91K | 556,703 |
| Matthew Maxwell Donley Chief Operating Officer | Feb 20, 2026 | Tax withholding | −32,901 | $14.40 | $473.77K | 662,900 |
| Peter Greenleaf Chief Executive Officer, Director | Feb 20, 2026 | Tax withholding | −100,171 | $14.40 | $1.44M | 1,744,866 |
| Greg Keenan SVP, Chief Medical Officer | Feb 2, 2026 | Tax withholding | −11,552 | $14.53 | $167.85K | 121,932 |
| Stephen P. Robertson EVP, General Counsel | Jan 2, 2026 | Tax withholding | −40,385 | $15.95 | $644.14K | 517,934 |
| Stephen P. Robertson EVP, General Counsel | Jan 2, 2026 | Award | +48,558 | – | – | 557,434 |
| Peter Greenleaf Chief Executive Officer, Director | Jan 2, 2026 | Award | +165,384 | – | – | 1,954,329 |
| Peter Greenleaf Chief Executive Officer, Director | Jan 2, 2026 | Tax withholding | −113,169 | $15.95 | $1.81M | 1,845,037 |
| Joseph M. Miller Chief Financial Officer | Jan 2, 2026 | Tax withholding | −40,161 | $15.95 | $640.57K | 589,127 |
| Joseph M. Miller Chief Financial Officer | Jan 2, 2026 | Award | +49,038 | – | – | 626,399 |
| Matthew Maxwell Donley Chief Operating Officer | Jan 2, 2026 | Award | +54,166 | – | – | 734,631 |
| Matthew Maxwell Donley Chief Operating Officer | Jan 2, 2026 | Tax withholding | −42,787 | $15.95 | $682.45K | 695,801 |
| Jeffrey Allen Bailey Director | Nov 21, 2025 | Tax withholding | −2,716 | $15.68 | $42.59K | 22,775 |
| Craig A. Johnson Director | Nov 21, 2025 | Tax withholding | −6,039 | $15.68 | $94.69K | 14,592 |
| Kevin Tang Director | Aug 5, 2025 | Buy | +200,000 | $11.68 | $2.34M | 11,329,500 |
| Kevin Tang Director | Aug 4, 2025 | Buy | +100,000 | $11.34 | $1.13M | 11,129,500 |
| Greg Keenan Chief Medical Officer | Aug 1, 2025 | Sale | −20,000 | $10.50 | $210.00K | 133,484 |
| Kevin Tang Director | Aug 1, 2025 | Buy | +1,000,000 | $10.12 | $10.12M | 11,029,500 |
| Greg Keenan Chief Medical Officer | Mar 7, 2025 | Sale | −8,305 | $8.23 | $68.35K | 153,484 |
| Matthew Maxwell Donley Chief Operating Officer | Mar 4, 2025 | Sale | −58,991 | $7.92 | $467.21K | 680,465 |
| Stephen P. Robertson EVP, General Counsel | Mar 4, 2025 | Sale | −57,607 | $7.92 | $456.25K | 509,276 |
| Kevin Tang Director | Mar 4, 2025 | Buy | +148,038 | $8.00 | $1.18M | 9,429,500 |
| Kevin Tang Director | Mar 4, 2025 | Buy | +500,000 | $7.92 | $3.96M | 9,929,500 |
| Kevin Tang Director | Mar 4, 2025 | Buy | +100,000 | $8.09 | $809.00K | 10,029,500 |
| Joseph M. Miller Chief Financial Officer | Mar 4, 2025 | Sale | −56,154 | $7.92 | $444.74K | 577,361 |
| Peter Greenleaf Chief Executive Officer, Director | Mar 4, 2025 | Sale | −164,947 | $7.92 | $1.31M | 1,788,945 |
| Matthew Maxwell Donley Chief Operating Officer | Mar 3, 2025 | Award | +135,567 | – | – | 805,358 |
| Matthew Maxwell Donley Chief Operating Officer | Mar 3, 2025 | Sale | −65,902 | $8.00 | $527.22K | 739,456 |
| Greg Keenan Chief Medical Officer | Mar 3, 2025 | Sale | −12,239 | $8.00 | $97.91K | 161,789 |
| Stephen P. Robertson EVP, General Counsel | Mar 3, 2025 | Award | +102,406 | – | – | 631,755 |
| Stephen P. Robertson EVP, General Counsel | Mar 3, 2025 | Sale | −64,872 | $8.00 | $518.98K | 566,883 |
| Kevin Tang Director | Mar 3, 2025 | Buy | +351,962 | $8.02 | $2.82M | 9,281,462 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aurinia Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,000 shares on Oct 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stephen P. Robertson Officer | Aug 21, 2026 | 47,000 | $719.10K | Aug 21, 2026 | Performance Stock Units |
| Gregory Keenan Former Affiliate | Jun 5, 2026 | 9,593 | $158.49K | Jun 5, 2026 | Exercise of Options Under a Registered Plan |
| Gregory Keenan Former Affiliate | Jun 4, 2026 | 25,000 | $408.44K | Jun 4, 2026 | Exercise of Options Under a Registered Plan |
| Gregory Keenan Officer | Jun 2, 2026 | 25,000 | $54.10M | Jun 2, 2026 | Exercise of options under a registered plan |
| Peter Greenleaf Former Affiliate | May 11, 2026 | 3,136,201 | $49.68M | May 11, 2026 | Exercise of options under a registered plan |
| Matthew Maxwell Donley Former Affiliate | May 11, 2026 | 717,688 | $11.37M | May 11, 2026 | Exercise of options under a registered plan |
| Joseph M. Miller Former Affiliate | May 11, 2026 | 500,503 | $7.93M | May 11, 2026 | Exercise of options under a registered plan |
See a number that looks wrong?